Health Care • Medical/Dental Instruments
$1.83 ▲ +0.16
(+9.58%)
MKT CAP: $6.1M • VOL: 30.9K
52W L $1 52W H $25
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
INBS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $3.1M | $3.1M | $1.3M |
| YoY Revenue Growth % | -1.9% | +147.6% | — |
| Gross Profit | $1.2M | $1.4M | — |
| Gross Margin % | 40.8% | 45.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.7M | -$10.3M | -$12.6M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$10.6M | -$10.2M | -$10.6M |
| EBITDA (Normalized) | -$10.5M | -$10.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.7M | -$9.6M | -$7.4M |
| Capital Expenditures (CapEx) | $231.8K | $221.4K | — |
| Free Cash Flow (FCF) | -$9.9M | -$9.8M | -$7.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $740.4K | $2.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.1M | $4.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INBS.